 |
|
Cancer: Another step towards medication
March 18, 2009Austrian scientists identify a potential tumor suppressor
The gene Myc is an important factor for the growth of organisms by cell division. It causes the production of a protein which, as a transcription factor, controls the expression of up to 15 % of all human genes. When this gene mutates to an oncogene, the cell proliferates excessively and apoptosis is inhibited. Thereby the gene plays a decisive role in the development of many tumors. The problem is that pharmacological substances do not target Myc as it does not have enzymatic activity of its own. Thus, scientists worldwide are trying to find alternative ways to inhibit this oncogene. A team of scientists led by Klaus Bister and Markus Hartl of the Institute of Biochemistry and the Centre for Molecular Biosciences of the University of Innsbruck may have made an important step towards achieving this goal.
Suppressing pathological cell growth
For the first time, the scientists have shown that Myc suppresses the expression of the gene BASP1. This evidence prompted them to test the effect of BASP1 on the oncogene. In cell experiments they proved that BASP1 specifically inhibits the uncontrolled proliferation of Myc. „Until now the precise biochemical function of BASP1 is unknown", Professor Bister explains. „However, in our experiments we have found clear evidence that Myc-induced cell transformation can be specifically inhibited by BASP1, and consequently, the gene functions as a tumor suppressor." This finding may facilitate the development of new drugs which keep the development of tumors under control.
University of Innsbruck
For the first time, the scientists have shown that Myc suppresses the expression of the gene BASP1. This evidence prompted them to test the effect of BASP1 on the oncogene. In cell experiments they proved that BASP1 specifically inhibits the uncontrolled proliferation of Myc. „Until now the precise biochemical function of BASP1 is unknown", Professor Bister explains. „However, in our experiments we have found clear evidence that Myc-induced cell transformation can be specifically inhibited by BASP1, and consequently, the gene functions as a tumor suppressor." This finding may facilitate the development of new drugs which keep the development of tumors under control.
University of Innsbruck
Oncogene Current Events and Oncogene News RSSAileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities.
NEDD9 Protein Supports Growth of Aggressive Breast Cancer
Researchers at Fox Chase Cancer Center have demonstrated that a protein called NEDD9 may be required for some of the most aggressive forms of breast cancer to grow. Their findings, based on the study of a mouse model of breast cancer, are presented in a recent issue of Cancer Research, available on-line now.
Lung cancer suppresses miR-200 to invade and spread
Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.
Mayo Clinic Researchers Find That Protein Believed to Protect Against Cancer Has a Mr. Hyde Side
In a biological rendition of fiction's Strange Case of Dr. Jekyll and Mr. Hyde, researchers from the Mayo Clinic campus in Florida and Harvard Medical School have found that a protein thought to protect against cancer development can actually spur the spread of tumors.
New hope for deadly childhood bone cancer
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults.
Researchers identify new, cancer-causing role for protein
The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.
Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.
Fox Chase Researchers Uncover One Force Behind the MYC Oncogene in Many Cancers
DLX5, a gene crucial for embryonic development, promotes cancer by activating the expression of the known oncogene, MYC, according to researchers from Fox Chase Cancer Center.
Duke scientists create airway spheres to study lung diseases
Using both animal and human cells, Duke University Medical Center scientists have demonstrated that a single lung cell can become one of two very different types of airway cells, which could lead to a better understanding of lung diseases.
1 gene that contributes to breast cancer's aggressive behavior identified
Aggressive forms of cancer are often driven by the abnormal over-expression of cancer-promoting genes, also known as oncogenes.
More Oncogene Current Events and Oncogene News Articles
|
Natural Obsessions: The Search for the Oncogene by Natalie Angier (Author) | |
 |
Klenow Enzyme, Oncogene - Size 0.08 mL - Model PF059--08ML - Each - Model PF059--08ML by Oncogene Liquid.Biological Activity: Contains 400 units; one unit is the amount of enzyme required to incorporate 10nmol of total nucleotide into acid-insoluble form in 30 minutes at 37 degrees C. |
|
p53 (Ab-2) (Pantropic) Monoclonal Antibody (100 µg.) by Oncogene Host: Mouse. Epitope/Immunogen: Amino acids 4655 of human p53. Positive Control: A-431 cells. Suggested tissue is breast carcinoma. Negative Control: SK-OV-3 cells. Suggested tissue is normal skin. Isotype: IgG1. Clone: PAb1801. Species_Reactivity: Human. Not mouse or rat. Solution. Reacts with human wild-type and mutant p53. For paraffin sections, pretreat with pepsin or use pressure cooker method. | |
 |
Oncogenes, Aneuploidy, and AIDS: A Scientific Life and Times of Peter H. Duesberg by Harvey Bialy (Author) The author is an unabashed friend of Peter Duesberg and makes no bones about it in this personalized account of some of what the transformation of classical molecular biology into biotechnology has wrought. Most people, even many molecular biologists, will either not know or remember that two of the great themes of modern medicine, AIDS and cancer genes, both directly derive from the pioneering work on retroviruses of Peter Duesberg and a handful of others in the 1970s. Thus Duesberg's more than two decade, ongoing theoretical and experimental critiques of the dominant etiological explanations in each of these fields comes from substantial scientific contributions over a highly distinguished professional career that not only placed him in the US National Academy of Sciences at the young... |
 |
Benign Prostatic Hyperplasia AHCPR Clinical Practice Guideline/Tumor Suppressor Genes in Human Cancer (NCME Video 658) Also With: Network For Continuing Medical Education (Primary Contributor), John Wasson (Primary Contributor), Daniel A Haber (Primary Contributor) In February, 1994, the Agency for Health Care Policy and Research (AHCPR) released a clinical practice guideline dealing with the diagnosis and treatment of benign prostatic hyperplasia. This telecourse presents highlights of that guideline. In the 1980's, the study of positive oncogenes was a major focus in the quest to understand the molecular origins of cancer. Today, tumor suppressor genes are sharing the spotlight and may exemplify an untapped resource for anticancer therapy. Dr. Haber demonstrates how recessive oncogenes, which normally control cell growth, allows cells to progress to malignancy when lost or inactivated. |
 |
Oncogene Proteins: Structure, Functions and Analyses by Peter B. Murphy (Editor), Jason R. Clarke (Editor) Oncogene proteins are proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene. This book presents the latest research in the field from around the world. |
|
|
[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg) by Oncogene [beta]-Amyloid Peptide (1-42), Human, Oncogene - Size 250 ug - Model PP69--25MG - Each (.25 MG) : Lyophilized.Synthetic peptide corresponding to amino acids 1-42 of the processed human amyloid peptide. Supplied in a form that is not neurotoxic prior to preincubation. The level of toxicity has recently been shown to correlate to the extent of beta sheet structure. Reconstitute with degassed HPLC grade deionized water. Purity: >95% by HPLC. FW: 4 kDa. |
 |
Oncogenes (The Jones and Bartlett Series in Biology) by Geoffrey M. Cooper (Author) The study of oncogenes and tumor suppressor genes continues to be a fast-moving area of science. This authoritative text provides a conceptual framework which allows students and professionals to understand this complex field. It also serves as a comprehensive reference for scientists engaged in oncogene research. The second edition of this text details major advances and developments in the field, such as the identification of many new tumor suppressor genes and the striking progress in understanding signal transduction pathways leading to cell proliferation. Oncogenes, Second Edition, addresses the needs of advanced undergraduates, graduate students, medical students, physicians, and scientists by examining the current state of oncogene study and where future... |
|
Oncogenes (Cancer Treatment and Research) by C.C. Benz (Editor), E.T. Liu (Editor) This topical, handy volume is the perfect guide for physicians or scientists not specializing in the field, but wishing to understand exciting recent developments in cellular and molecular biology relevant to oncogene research. The terminology used in discussing oncogenes and their products is straightforwardly defined, and the concepts crucial to an understanding of oncogene research are clearly presented. Key topics are explored, including assay techniques used in molecular biology; methods for assessing behavior of normal genes and oncogenes; DNA and RNA tumor viruses; viruses inducing immunodeficiency; cellular proto-oncogenes and their relation to retroviral oncogenes; and possible roles of gene amplification and mutation, chromosomal translocation, and cellular growth factors in... | |
|
|
[beta]-amyloid Peptide (1-40, Gln22), Human, Oncogene - Size 500 Ug - Model Pp68--5mg - Each (1 Mg) by Oncogene [beta]-Amyloid Peptide (1-40, Gln22), Human, Oncogene - Size 500 ug - Model PP68--5MG - Each (1 MG) : Lyophilized.Synthetic peptide corresponding to amino acids 1-40 of the processed human amyloid peptide with a substitution of Gln22. Supplied in a form that is not neurotoxic prior to preincubation. The level of toxicity has recently been shown to correlate to the extent of beta sheet structure. Reconstitute with degassed HPLC grade deionized water. Purity: >99% by HPLC. FW: 4 kDa. |
| © 2009 BrightSurf.com |